Volume 20, Issue 3 pp. 122-126
LEADING ARTICLE

Corticosteroid therapy in drug-induced liver injury: Pros and cons

Ping Fang Hu

Ping Fang Hu

Department of Gastroenterology, Changzheng Hospital, Second Military Medical University, Shanghai, China

Search for more papers by this author
Wei Fen Xie

Corresponding Author

Wei Fen Xie

Department of Gastroenterology, Changzheng Hospital, Second Military Medical University, Shanghai, China

Correspondence

Wei Fen Xie, Department of Gastroenterology, Changzheng Hospital, Second Military Medical University, No. 415 Fengyang Road, Shanghai 200003, China.

Email: [email protected]

Search for more papers by this author
First published: 23 December 2018
Citations: 52
Abbreviations: AH, alcoholic hepatitis; AHFSG, Acute Hepatic Failure Study Group; AIH, autoimmune hepatitis; ALF, acute liver failure; ALT, alanine aminotransferase; CAH, chronic active hepatitis; DILI, drug-induced liver injury; DM, diabetes mellitus; EASL, European Association for the Study of the Liver; GI, gastrointestinal; INR, international normalized ratio; NAC, N-acetylcysteine; TB, total bilirubin; TCM, Traditional Chinese Medicine; UDCA, ursodeoxycholic acid; ULN, upper limit of normal.

Abstract

Drug-induced liver injury (DILI) is a liver toxicity induced by a drug or its metabolite. The incidence of DILI continues to increase and it has been an enormous challenge worldwide, while the prognosis is not optimistic. Currently, the most effective treatment for DILI is to suspend the offending drug(s) and to avoid re-exposure, with no definitive therapy available for idiosyncratic DILI with or without acute liver failure. Given the anti-inflammatory effects of corticosteroids, they have been widely used in DILI in clinical practice, although their efficacy remains controversial. Several studies have shown their beneficial effects but a few reports have refuted the efficacy of corticosteroids in treating patients with DILI. In this review, we summarized the history and current status of corticosteroid use in liver diseases and the pros and cons of corticosteroid treatment in DILI, and we explored the DILI candidates who may benefit from corticosteroid therapy, the administration route and dosage, and the adverse effects related to corticosteroid use.

CONFLICT OF INTEREST

The authors have no conflict of interest to declare.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.